RECALL-VAX RV02

RECALL-VAX RV02 is a preclinical therapeutic vaccine candidate developed by Intellect Neurosciences, Inc. It is part of the proprietary RECALL-VAX active vaccine platform, which is designed to generate highly specific antibodies against pathological proteins. Specifically, RV02 targets abnormal delta tau (ΔTau) protein, a key pathological hallmark of Alzheimer's disease and related tauopathies. The vaccine is designed as a chimeric peptide comprising a short human antigen B-cell neoepitope linked to a bacterial T-cell epitope (such as tetanus toxoid) to stimulate an immune response. It has both prophylactic and therapeutic potential for Alzheimer's disease, Frontotemporal Dementia, Progressive Supranuclear Palsy, and other neurodegenerative disorders.

Other names

Anti-delta tau RECALL-VAXRECALL-VAX (RV02)